AbbVie reported solid fourth-quarter and full-year 2025 results, delivering full-year net revenues of $61.16 billion, up 8.6% year over year, despite a significant drag from acquired IPR&D and milestone expenses. On a GAAP basis, full-year diluted EPS declined 1.3% to $2.36, while adjusted diluted EPS decreased 1.2% to $10.00, reflecting an unfavorable $2.76 per-share impact from 2025 acquired IPR&D and milestones.

Growth was led by the immunology and neuroscience portfolios, which more than offset continued Humira erosion. Full-year immunology revenues rose 14.0% to $30.41 billion, driven by strong performance from Skyrizi ($17.56 billion) and Rinvoq ($8.30 billion). Neuroscience revenues increased 19.6% to $10.77 billion, supported by Vraylar, Botox Therapeutic, and migraine brands Ubrelvy and Qulipta. Oncology revenues grew modestly to $6.66 billion, while aesthetics revenues declined 6.1% to $4.86 billion.

In the fourth quarter, AbbVie posted net revenues of $16.62 billion, up 10.0% year over year. Adjusted diluted EPS was $2.71, compared with GAAP diluted EPS of $1.02, reflecting a $0.71 per-share headwind from acquired IPR&D and milestone expenses. For 2026, the company issued adjusted diluted EPS guidance of $14.37 to $14.57, excluding any unfavorable impact from acquired IPR&D and milestones, signaling confidence in continued growth momentum.

Source: AbbVie, PRNewswire, February 4, 2026.